ORIGINAL RESEARCH
Published on 30 Apr 2025
Dalpiciclib plus aromatase inhibitor versus neoadjuvant chemotherapy for ER-positive, HER2-negative breast cancer
doi 10.3389/fonc.2025.1566146
- 746 views
125
Total downloads
1,255
Total views and downloads
Submit your idea
You will be redirected to our submission process.
Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.
Submit your idea
You will be redirected to our submission process.